Indian pharmaceutical company Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) (BSE:524715) and Israel-based Moebius Medical Limited announced on Friday that the US Food and Drug Administration (FDA) has granted Fast Track designation to MM-II (Large Liposomes of DPPC and DMPC) for treating osteoarthritis knee pain.
Fast Track designation expedites the development and review process for therapies addressing unmet medical needs. This allows for more frequent interaction with the FDA during clinical development and potentially faster approval.
MM-II, a novel non-opioid product, is currently in Phase 2b trials with promising results. Sun Pharma and Moebius Medical are planning confirmatory Phase 3 trials.
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Neuspera Medical names new chief operating officer
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Diamyd Medical seeks Fast-Track approval for Type 1 Diabetes immunotherapy
Sun Pharma and Moebius Medical's MM-II receives Fast Track designation for osteoarthritis knee pain
Vivet Therapeutics receives Orphan Drug Designation from European Commission for VTX-806
SFA Therapeutics names new director of Biostatistics
FDA approves Azurity Pharmaceuticals' Nymalize oral solution in 30 mg/5 mL prefilled ENFit syringe